Tailwinds' Take: with their sales team now fully integrated into the company, along with an industry leading product line, we can expect to see more customer announcements like this going forward.  SOMERSET, N.J, Jan. 29, 2018 (GLOBE NEWSWIRE) -- MTBC...
MTBC (NASDAQ) is poised to breakout on recent news. After trading down since its IPO in 2014 on less than 5,000 shares/day, MTBC skyrocketed in April of this year (April) on over 20 million in volume. After a volatile...
We have made two changes in the Tailwinds Select Portfolio. MTBC added to the Portfolio. Our discipline is that new names get added to the Portfolio at an average weighting. Since we now have 15 stocks in the Portfolio, MTBC...
Tailwinds' Take: 2017 was a solid year for MTBC operationally as they integrated a major acquisition, returned to positive cash flow, and repaired their balance sheet. 2018 should be an exciting year of both organic growth and acquisitions. SOMERSET, N.J.,...
SOMERSET, N.J., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Medical Transcription Billing, Corp. ("MTBC" or the "Company") (NASDAQ: MTBC) (NASDAQ: MTBCP), a leading provider of proprietary, cloud-based healthcare IT solutions and services, today announced the closing of its public offering...
SOMERSET, N.J, Dec. 01, 2017 (GLOBE NEWSWIRE) -- MTBC (NASDAQ:MTBC) (NASDAQ: MTBCP), a leading provider of cloud-based healthcare IT solutions and services, today announced that MTBC's Board of Directors has unanimously approved the recommendation of its  Founder, Chairman and CEO, Mahmud...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.